NEW YORK ( TheStreet) -- Cell Therapeutics (Nasdaq: CTIC) is trading at unusually high volume Friday with 58 million shares changing hands. It is currently at 8.9 times its average daily volume and trading down one cent (-2.5%) at 43 cents as of 11:26 a.m. ET. Cell has a market cap of $301.8 million and is part of the health care sector and drugs industry. Cell Therapeutics, Inc., a biopharmaceutical company, develops, acquires, and commercializes oncology products for the treatment of cancer. TheStreet Ratings rates Cell as sell. The company's weaknesses can be seen in multiple areas, such as its generally disappointing historical performance in the stock itself and poor profit margins. You can view the full Cell Ratings Report. See all heavy volume stocks in our stocks moving on unusual volume list or get investment ideas from our investment research center. Interested in other stocks that are falling on unusually high volume? Get free SMS text alerts sent to you when the action happens by texting HVDOWN to 95370 or select from multiple alert options.
More from Markets
Stocks End Higher on Solid Earnings From JPMorgan Chase, UnitedHealth and J&J
Stocks finish near record highs Tuesday as strong earnings reports from JPMorgan Chase, UnitedHealth and Johnson & Johnson override investors' lingering questions about the fate of U.S.-China trade talks.
Sectors to Keep an Eye on as Earnings Season Heats Up
Here are two and a half sectors to pay attention to during the earnings season. Hint: one has heavy exposure to China.